Miller T P, Jones S E
Lancet. 1979 Feb 17;1(8112):358-60. doi: 10.1016/s0140-6736(79)92894-0.
22 patients with localised (stage I or II) diffuse lymphoma were treated with chemotherapy at the time of diagnosis. 14 patients received chemotherapy as the only treatment, and 8 received chemotherapy plus local irradiation. Doxorubicin-containing drug regimens were used in 20 patients. All 22 patients achieved a complete remission and remain alive with a median survival from the time of diagnosis of 27+ months. 21 patients (95%) have remained continuously free of disease with a median disease-free survival from the completion of chemotherapy of 23+ months. These findings provide a strong rationale for further clinical trials of chemotherapy alone or chemotherapy followed by regional radiotherapy for localised stages of diffuse lymphoma.
22例局限性(I期或II期)弥漫性淋巴瘤患者在确诊时接受了化疗。14例患者仅接受化疗,8例患者接受化疗加局部放疗。20例患者使用了含阿霉素的化疗方案。所有22例患者均实现完全缓解,自确诊起中位生存期为27多个月,且仍存活。21例患者(95%)持续无病生存,自化疗结束起无病生存期的中位数为23多个月。这些发现为进一步开展针对局限性弥漫性淋巴瘤单独化疗或化疗后区域放疗的临床试验提供了有力依据。